Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2024-08-14 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
PYC to Start Human Trials in Second Blinding Eye Disease 4 pages 293.7KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from PYC Therapeutics about the commencement of human clinical trials for a drug candidate targeting Autosomal Dominant Optic Atrophy (ADOA). It includes information about regulatory approvals, study design, endpoints, and the company's drug development programs. The content focuses on clinical trial initiation and drug development progress rather than financial results, management changes, or regulatory certifications. It is not a financial report, earnings release, or management discussion. The document is a corporate announcement about clinical trial commencement and related scientific and regulatory details, which fits best under the category of a general regulatory announcement or compliance update. Given the absence of financial data or formal report structure, the most appropriate classification is Regulatory Filings (RNS). The document length (10,773 characters) is substantial, indicating it is not a brief report publication announcement but a full announcement.
2024-08-14 English
Canaccord Genuity Growth Conference Presentation 15 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is titled as a 'Canaccord Genuity Growth Conference Presentation' and contains detailed slides about PYC Therapeutics' business, pipeline, clinical progress, and strategy. It is a presentation given at an investor conference, focusing on company overview, drug development pipeline, clinical trial updates, and strategic outlook. There are no financial statements, audit opinions, or regulatory certifications. The content is typical of an investor presentation aimed at providing detailed information to investors and analysts about the company's business and prospects. Therefore, the document fits the category of an Investor Presentation (IP). The document length (13,328 characters) and detailed content support this classification with high confidence.
2024-08-12 English
Visual Improvement in Multiple RP11 Patients 6 pages 411.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from PYC Therapeutics about clinical trial results and progress for their drug candidate VP-001 targeting Retinitis Pigmentosa type 11 (RP11). It includes detailed clinical data, patient cohort updates, trial phases, and future plans for registrational trials. The document is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is a detailed update on clinical trial progress and drug development, typical of a Capital/Financing Update or clinical progress announcement. There is no indication of earnings data, board changes, voting results, or legal proceedings. The document is lengthy (15,000 characters) and contains substantive data on clinical trial outcomes and development plans. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to the progress and development of a drug candidate which impacts the company's capital and financing outlook.
2024-08-11 English
RP11 Clinical Trial Update 9 pages 729.6KB
Capital/Financing Update Classification · 95% confidence The document is a detailed clinical trial update from PYC Therapeutics regarding their drug candidate for Retinitis Pigmentosa type 11 (RP11). It includes extensive data on patient responses, dosing cohorts, clinical trial progress, and future plans. The content is scientific and clinical in nature, focusing on trial results and development milestones rather than financial results or regulatory filings. It is not an earnings release, annual report, or management discussion. It is also not a regulatory filing or announcement of a report but a substantive update on clinical trial progress and data. This type of document fits best under the category of a Capital/Financing Update (CAP) because it relates to the progress of clinical trials which are critical to the company's capital and financing activities, especially in biotech firms where clinical trial updates are material to investors and financing decisions. The document length (15,000 characters) and detailed data confirm it is a full update, not a brief announcement or presentation. Therefore, the most appropriate classification is CAP with high confidence.
2024-08-04 English
RP11 Clinical Trial Update - Amended 11 pages 881.8KB
Regulatory Filings Classification · 95% confidence The document is an extensive clinical trial update from PYC Therapeutics regarding their RP11 drug candidate. It includes detailed data on patient responses, clinical trial progress, and future study plans. The content is focused on clinical trial results and development updates rather than financial performance, regulatory certifications, or shareholder matters. It is not an earnings release, annual report, or regulatory filing. The document is a detailed announcement of clinical trial progress and data, typical of a clinical trial update or development update. Given the filing categories, the closest match is 'Regulatory Filings (RNS)' as it is a general regulatory announcement that does not fit into other specific categories like earnings, capital updates, or management changes. The document is not a report publication announcement since it contains substantive data and figures, not just a notice of report availability. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2024-08-04 English
Completion of Small Shareholding Sale Facility 2 pages 211.0KB
Transaction in Own Shares Classification · 95% confidence The document is an announcement from PYC Therapeutics Limited regarding the completion of a Small Shareholding Sale Facility, which allowed shareholders with small holdings to sell their shares without brokerage fees. It provides details on the number of shares sold, the price, and payment dispatch. There is no financial data, no report attached or referenced as being published, and no mention of regulatory filings or certifications. The document is a specific announcement about a share sale facility completion, which fits best under the category of Transaction in Own Shares (POS), as it relates to the company facilitating the sale of its own shares held by small shareholders.
2024-08-01 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.